OOIR: Observatory of International Research

Papers

(The TQCC of Diabetes Obesity & Metabolism is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
COVID‐19 infection may cause ketosis and ketoacidosis	325
Prevalence of co‐morbidities and their association with mortality in patients with COVID‐19: A systematic review and meta‐analysis	292
An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines	275
Proportion of newly diagnosed diabetes in COVID‐19 patients: A systematic review and meta‐analysis	187
Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID‐19	179
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension	152
The evolving story of incretins (GIP and GLP‐1) in metabolic and cardiovascular disease: A pathophysiological update	135
Obesity as a multisystem disease: Trends in obesity rates and obesity‐related complications	134
The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity	130
Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study	116
The clinical characteristics and outcomes of patients with diabetes and secondary hyperglycaemia with coronavirus disease 2019: A single‐centre, retrospective, observational study in Wuhan	116
Prediabetes and the risk of heart failure: A meta‐analysis	103
Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review	103
Sodium‐glucose co‐transporter‐2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta‐analysis of randomized controlled trials	91
Influence of diabetes mellitus on the severity and fatality of SARS‐CoV‐2 (COVID‐19) infection	88
Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets	87
Hybrid closed‐loop therapy: Where are we in 2021?	86
Comparative efficacy of glucose‐lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta‐analysis	81
Exposure to dipeptidyl‐peptidase‐4 inhibitors and COVID‐19 among people with type 2 diabetes: A case‐control study	81
The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk	78
Effect of setmelanotide, a melanocortin‐4 receptor agonist, on obesity in Bardet‐Biedl syndrome	77
Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes	76
Comparison of MiniMed 780G system performance in users aged younger and older than 15 years: Evidence from 12 870 real‐world users	74
Why is hyperglycaemia worsening COVID‐19 and its prognosis?	71
Does poor glycaemic control affect the immunogenicity of the COVID‐19 vaccination in patients with type 2 diabetes: The CAVEAT study	70

Sodium‐glucose co‐transporter‐2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials	64
Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme	63
Relationship between obesity and severe COVID‐19 outcomes in patients with type 2 diabetes: Results from the CORONADO study	63
Obesity as a risk factor for COVID‐19 mortality in women and men in the UK biobank: Comparisons with influenza/pneumonia and coronary heart disease	62
Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: Results from the 26‐week PRONTO‐T1D study	59
The PREVIEW intervention study: Results from a 3‐year randomized 2 x 2 factorial multinational trial investigating the role of protein, glycaemic index and physical activity for prevention	58
Association of obesity with postacute sequelae of COVID‐19	58
Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct‐acting antiviral therapy: A prospective study	58
Hybrid closed‐loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: A double‐blind, multicentre, multinational, randomized, crossover st	55
Association between prediabetes and adverse outcomes in heart failure	55
A clinical overview of non‐alcoholic fatty liver disease: A guide to diagnosis, the clinical features, and complications—What the non‐specialist needs to know	54
Glucagon‐like peptide‐1 receptor agonists improve biomarkers of inflammation and oxidative stress: A systematic review and meta‐analysis of randomised controlled trials	53
Validation of distinct type 2 diabetes clusters and their association with diabetes complications in the DEVOTE, LEADER and SUSTAIN‐6 cardiovascular outcomes trials	53
Comparable COVID‐19 outcomes with current use of GLP‐1 receptor agonists, DPP‐4 inhibitors or SGLT‐2 inhibitors among patients with diabetes who tested posi	51
Remission of type 2 diabetes following long‐term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11‐year data from a real‐world registry study	51
Evidence‐based weight loss interventions: Individualized treatment options to maximize patient outcomes	51
The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 (GLP‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective	51
The dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc	48
Diabetes, obesity and COVID‐19: A complex interplay	46
Strategies for overcoming therapeutic inertia in type 2 diabetes: A systematic review and meta‐analysis	46
COVID‐19 fatality prediction in people with diabetes and prediabetes using a simple score upon hospital admission	45
Effectiveness and safety of sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors in older adults with type 2 diabetes: A nationwide population‐based study	45
Efficacy and safety of once‐weekly semaglutide versus once‐daily sitagliptin as add‐on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30‐week, double‐blind, phase 3a, ran	44
Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study	44
Humoral immune response to COVID‐19 vaccination in diabetes is age‐dependent but independent of type of diabetes and glycaemic control: The prospective COVAC‐DM cohort study	44
Predictors of time in target glucose range in real‐world users of the MiniMed 780G system	42
Lower cardiorenal risk with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A	42
Effects of 6 weeks of treatment with dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo‐controlle	42
Glucagon‐like peptide‐1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta‐analysis	42
Sodium‐glucose co‐transporter‐2 inhibitors with and without metformin: A meta‐analysis of cardiovascular, kidney and mortality outcomes	40
Understanding the clinical implications of differences between glucose management indicator and glycated haemoglobin	40
Non‐alcoholic fatty liver disease‐related risk of cardiovascular disease and other cardiac complications	40
Intermittent fasting and ‘metabolic switch’: Effects on metabolic syndrome, prediabetes and type 2 diabetes	40
Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: A review of pathophysiology, mechanisms, and evidence from recent trials	39
Prevalence of residual inflammatory risk and associated clinical variables in patients with type 2 diabetes	39
Pioglitazone and bariatric surgery are the most effective treatments for non‐alcoholic steatohepatitis: A hierarchical network meta‐analysis	38
Undertreatment of cardiovascular risk factors in the type 1 diabetes exchange clinic network (United States) and the prospective diabetes follow‐up (Germany/Austria) registries	38
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP‐1RA treatment: A subgroup analysis from the FIDELIO‐DKD trial	37
Real‐world performance of the MiniMed™ 670G system in Europe	37
Effects of the COVID‐19 lockdown on glycaemic control in subjects with type 2 diabetes: the glycalock study	37
Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID‐19: Design and rationale for the DARE‐19 study	37
Dedicated kidney disease‐focused outcome trials with sodium‐glucose cotransporter‐2 inhibitors: Lessons from CREDENCE and expectations from DAPA‐HF, DAPA‐CKD, and EMPA‐KIDNEY	36
COVID‐19, ketoacidosis and new‐onset diabetes: Are there possible cause and effect relationships among them?	36
Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo‐controlled study	36
Diabetes duration and glycaemic control as predictors of cardiovascular disease and mortality	35
Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT‐2 study): 52‐week results from a randomized controlled trial	35
Technology in the management of type 2 diabetes: Present status and future prospects	35
Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes	35
Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective	35
Add‐on therapy with dapagliflozin under full closed loop control improves time in range in adolescents and young adults with type 1 diabetes: The DAPADream study	35

Mechanisms underlying the metabolic actions of testosterone in humans: A narrative review	34
Long‐term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52‐week, open‐label, mul	34
Sodium‐glucose cotransporter‐2 inhibition reduces cellular senescence in the diabetic kidney by promoting ketone body‐induced NRF2 activation	34
Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials	34
Inhibition of fatty acid synthase with FT‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non‐alcoholic fatty liver disease: Results from two early‐phas	34
Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis	34
Sodium‐glucose co‐transporter‐2 inhibitors and major adverse limb events: A trial‐level meta‐analysis including 51 713 individuals	34
Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss	33
C‐peptide determination in the diagnosis of type of diabetes and its management: A clinical perspective	32
Sodium‐glucose co‐transporter‐2 inhibitors and all‐cause mortality: A meta‐analysis of randomized controlled trials	32
Patients' preferences for once‐daily oral versus once‐weekly injectable diabetes medications: The REVISE study	32
Global mortality of diabetic foot ulcer: A systematic review and meta‐analysis of observational studies	32
A phase 3 randomized clinical trial using a once‐weekly glucagon‐like peptide‐1 receptor agonist in adolescents and young adults with hypothalamic obesity	32
Sodium‐glucose co‐transporter‐2 inhibitors and susceptibility to COVID‐19: A population‐based retrospective cohort study	31
Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment	31
Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes	31
The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial	31
Benefits of continuous positive airway pressure on glycaemic control and insulin resistance in patients with type 2 diabetes and obstructive sleep apnoea: A meta‐analysis	30
Use of dipeptidyl peptidase‐4 inhibitors and prognosis of COVID‐19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study	30
Semaglutide for the treatment of overweight and obesity: A review	30
Liraglutide treatment in overweight and obese patients with type 1 diabetes: A 26‐week randomized controlled trial; mechanisms of weight loss	30
Sodium‐glucose co‐transporter‐2 inhibitors for the prevention of cardiorenal outcomes in type 2 diabetes: An updated meta‐analysis	30
Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24‐week, randomized, double‐blind, placebo‐controlled, dose‐ranging phase 2b trial	30
Assessing the cost‐effectiveness of sodium–glucose cotransporter‐2 inhibitors in type 2 diabetes mellitus: A comprehensive economic evaluation using clinical trial and real‐world evidence	29
Machine‐learning–based early prediction of end‐stage renal disease in patients with diabetic kidney disease using clinical trials data	29
Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus trea	28
Risk of new‐onset type 2 diabetes in 600 055 people after COVID‐19: A cohort study	28
Efficacy and safety of cotadutide, a dual glucagon‐like peptide‐1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease	28
Effects of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER	28
Real‐world performance of hybrid closed loop in youth, young adults, adults and older adults with type 1 diabetes: Identifying a clinical target for hybrid closed‐loop use	27
The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: Results of a pilot randomized, doubl	27
The J‐shaped relationship between body mass index and mortality in patients with COVID‐19: A dose‐response meta‐analysis	27
Semaglutide once weekly in people with type 2 diabetes: Real‐world analysis of the Canadian LMC diabetes registry (SPARE study)	27
Relationship between improvement of glycaemic control and reduction of major cardiovascular events in 15 cardiovascular outcome trials: A meta‐analysis with meta‐regression	27
An overview of obesity mechanisms in humans: Endocrine regulation of food intake, eating behaviour and common determinants of body weight	27
Body mass index and the risk of COVID‐19 across ethnic groups: Analysis of UK Biobank	27
Chronic kidney disease in type 2 diabetes: Implications for managing glycaemic control, cardiovascular and renal risk	27
Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study	27
Incretin combination therapy for the treatment of non‐alcoholic steatohepatitis	26
Preclinical evaluation of tyrosine kinase 2 inhibitors for human beta‐cell protection in type 1 diabetes	26
A phase 1 multiple‐ascending dose study of tirzepatide in Japanese participants with type 2 diabetes	26
Licogliflozin versus placebo in women with polycystic ovary syndrome: A randomized, double‐blind, phase 2 trial	26
Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison	26
Greater variability in lipid measurements associated with cardiovascular disease and mortality: A 10‐year diabetes cohort study	26
Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized con	26
Metabolic surgery for the treatment of type 2 diabetes: A network meta‐analysis of randomized controlled trials	25
Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon‐like peptide‐1/glucagon receptor agonist SAR425899 in comparison with liraglutide	25
Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE‐TIMI 58 study	25
Intrahepatic fat, irrespective of ethnicity, is associated with reduced endogenous insulin clearance and hepatic insulin resistance in obese youths: A cross‐sectional and longitudinal study from the <	25
HbA1c and brain health across the entire glycaemic spectrum	25
Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA‐REG OUTCOME trial	25
Admission fasting blood glucose predicts 30‐day poor outcome in patients hospitalized for COVID‐19 pneumonia	25
Metabolically healthy obesity and cardiovascular events: A nationwide cohort study	25
Safety, efficacy and pharmacokinetics of repeat subcutaneous dosing of avexitide (exendin 9‐39) for treatment of post‐bariatric hypoglycaemia	25
Effects of hyperglycaemia on complications of COVID‐19: A meta‐analysis of observational studies	24
The metabolic triad of non‐alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment	24
Improved postprandial glucose control with ultra rapid lispro versus lispro with continuous subcutaneous insulin infusion in type 1 diabetes: PRONTO‐Pump‐2	24
Cardiorenal outcomes with dapagliflozin by baseline glucose‐lowering agents: Post hoc analyses from DECLARE‐TIMI 58	24
Effect of once‐weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial	24
Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT	24
A real‐world study of user characteristics, safety and efficacy of open‐source closed‐loop systems and Medtronic 670G	23
New insights into the treatment of obesity	23
The impact of the COVID‐19 pandemic on glycaemic control in people with diabetes: A systematic review and meta‐analysis	23
Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the United States	23
Metformin‐induced vitamin B12 deficiency can cause or worsen distal symmetrical, autonomic and cardiac neuropathy in the patient with diabetes	23
Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study	23
Performance of a factory‐calibrated, real‐time continuous glucose monitoring system during elective abdominal surgery	23
Benefit/risk profile of dapagliflozin 5 mg in the DEPICT‐1 and ‐2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m²	23
Obesity as a driver of international differences in COVID‐19 death rates	23
Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline cha	23
Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses	23
Efficacy and safety of insulin glargine/lixisenatide fixed‐ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic	23
The effect of mirabegron on energy expenditure and brown adipose tissue in healthy lean South Asian and Europid men	22
Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: A systematic literature review	22
Association of lactation with maternal risk of type 2 diabetes: A systematic review and meta‐analysis of observational studies	22
Effects of sodium‐glucose cotransporter 2 inhibitors on serum uric acid in patients with type 2 diabetes mellitus: A systematic review and network meta‐analysis	22
Efficacy and safety of insulin glargine/lixisenatide fixed‐ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabet	22
Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA‐REG OUTCOME trial	22
Use of once‐weekly semaglutide in patients with type 2 diabetes in routine clinical practice: Results from the SURE Canada multicentre, prospective, observational study	22
Interconnection between cardiovascular, renal and metabolic disorders: A narrative review with a focus on Japan	22

Efficacy and safety of once‐monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo‐controlled, 16‐week randomized dose‐finding study	22
Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus	22
Effects of insulin degludec and insulin glargine U300 on glycaemic stability in individuals with type 1 diabetes: A multicentre, randomized controlled crossover study	22
Lower risk of hospitalization for heart failure, kidney disease and death with sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors in type 2 diabetes regardless	21
Effects of liraglutide on the metabolism of triglyceride‐rich lipoproteins in type 2 diabetes	21
Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52‐week outcomes from the DEPICT‐1 and ‐2 studies	21
Efficacy and safety of 28‐day treatment with oral insulin (ORMD‐0801) in patients with type 2 diabetes: A randomized, placebo‐controlled trial	21
Association between visit‐to‐visit HbA1c variability and the risk of cardiovascular disease in patients with type 2 diabetes	21
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon‐like peptide‐1 receptor agonistBI456906	21
Rationale and design of the phase 3a development programme (ONWARDS 1–6 trials) investigating once‐weekly insulin icodec in diabetes	20
Current trends in diabetes mellitus database research in Japan	20
Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD‐11	20
Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial	20
Effects of a 6‐month, low‐carbohydrate diet on glycaemic control, body composition, and cardiovascular risk factors in patients with type 2 diabetes: An open‐label randomized controlled trial	20
Validation of obesity‐related diagnosis codes in claims data	20
The sodium‐glucose co‐transporter‐2 inhibitor ertugliflozin modifies the signature of cardiac substrate metabolism and reduces cardiac mTOR signalling, endoplasmic reticulum stress and apop	20
Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon‐like peptide‐1 receptor agonists or sodium‐glucose cotransporter‐2 inhibitors: A real‐world study in two Ita	20
Metabolic surgery: A clinical update	19
Prevalence of obesity and associated complications in China: A cross‐sectional, real‐world study in 15.8 million adults	19
Effects of glucose‐lowering agents on cardiovascular and renal outcomes in subjects with type 2 diabetes: An updated meta‐analysis of randomized controlled trials with external adjudication of events	19
Efficacy and safety of imeglimin add‐on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double‐blind, placebo‐controlled phase 3 trial with a 36‐we	19
Use of sodium‐glucose co‐transporter‐2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendations	19
Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin‐treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial	19
Sotagliflozin for patients with type 2 diabetes: A systematic review and meta‐analysis	19
Semaglutide delays 4‐hour gastric emptying in women with polycystic ovary syndrome and obesity	19
What have we learned about renal protection from the cardiovascular outcome trials and observational analyses with SGLT2 inhibitors?	19
Ultra‐rapid‐acting insulins for adults with diabetes: A systematic review and meta‐analysis	19
Impact of periodontal therapy on systemic markers of inflammation in patients with metabolic syndrome: A randomized clinical trial	19
Gastric emptying of solutions containing the natural sweetener erythritol and effects on gut hormone secretion in humans: A pilot dose‐ranging study	18
Effects of glucagon‐like peptide‐1 receptor agonists on cardiovascular and renal outcomes: A meta‐analysis and meta‐regression analysis	18
Risk of diabetic macular oedema with sodium‐glucose cotransporter‐2 inhibitors in type 2 diabetes patients: A multi‐institutional cohort study in Taiwan	18
ADO09, a co‐formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes	18
Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add‐on to metformin in patients with type 2 diabetes	18
Lower risk of severe hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL in participants with type 1 diabetes: A meta‐analysis of 6‐month	18
Pharmacokinetics, safety, tolerability and efficacy of cotadutide, a glucagon‐like peptide‐1 and glucagon receptor dual agonist, in phase 1 and 2 trials in overweight or obese participants	18
Use of inhaled corticosteroids and the risk of developing type 2 diabetes in patients with chronic obstructive pulmonary disease	18
Real‐world use of cardioprotective glucose‐lowering drugs in patients with type 2 diabetes and cardiovascular disease: A Danish nationwide cohort study, 2012 to 2019	18
Pharmacokinetic and dose‐finding studies on efpeglenatide in patients with type 2 diabetes	18
Efficacy and safety of high‐dose glucagon‐like peptide‐1, glucagon‐like peptide‐1/glucose‐dependent insulinotropic peptide, and glucagon‐like peptide‐1/glucagon receptor agonists in type 2 diabetes	18
Prediction of heart failure outcomes in patients with type 2 diabetes mellitus: Validation of the Thrombolysis in Myocardial Infarction Risk Score for Heart Failure in Diabetes (TRS‐HF_DM	18
Weight loss interventions and nonalcoholic fatty liver disease: Optimizing liver outcomes	18
Effectiveness of a closed‐loop control system and a virtual educational camp for children and adolescents with type 1 diabetes: A prospective, multicentre, real‐life study	17
Positioning sulphonylureas in a modern treatment algorithm for patients with type 2 diabetes: Expert opinion from a European consensus panel	17
Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the EMPA‐REG OUTCOME trial with a focus on Asia	17
The cost‐effectiveness of dapagliflozin in treating high‐risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE‐TIMI 58 trial	17
Comparative efficacy and safety of glucose‐lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta‐analysis	17
Effect of once‐weekly semaglutide versus thrice‐daily insulin aspart, both as add‐on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11):	17
Patients with highly unstable type 1 diabetes eligible for islet transplantation can be managed with a closed‐loop insulin delivery system: A series of N‐of‐1 randomized controlled trials	17
Reducing the need for carbohydrate counting in type 1 diabetes using closed‐loop automated insulin delivery (artificial pancreas) and empagliflozin: A randomized, controlled, non‐inferiority, crossove	17
Understanding the place for GLP‐1RA therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection	17
Re‐examining the widespread policy of stopping sodium‐glucose cotransporter‐2 inhibitors during acute illness: A perspective based on the updated evidence	17
Glucagon‐like peptide‐1 receptor agonists and the appropriate measurement of gastric emptying	17
Dose‐dependent accumulation of glucose in the intestinal wall and lumen induced by metformin as revealed by ¹⁸F‐labelled fluorodeoxyglucose positron emission tomography‐MRI	17
Changes in plasma and urine metabolites associated with empagliflozin in patients with type 1 diabetes	17
Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise: 6‐month follow‐up from US real‐world data	17
Vitamin D for treatment of non‐alcoholic fatty liver disease detected by transient elastography: A randomized, double‐blind, placebo‐controlled trial	17
Combined therapy with CD4⁺CD25highCD127⁻ T regulatory cells and anti‐CD20 antibody in recent‐onset type 1 diabetes is superior to monotherapy: Ra	17
Longevity of the novel ConvaTec infusion set with Lantern technology	17
Ladarixin, an inhibitor of the interleukin‐8 receptors CXCR1 and CXCR2, in new‐onset type 1 diabetes: A multicentre, randomized, double‐blind, placebo‐controlled trial	16
The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER an	16
Semaglutide improves health‐related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)	16
Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase‐4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the ra	16
Nasal glucagon as a viable alternative for treating insulin‐induced hypoglycaemia in Japanese patients with type 1 or type 2 diabetes: A phase 3 randomized crossover study	16
Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once‐weekly dosing for the treatment of patients with	16
Beneficial actions of a long‐acting apelin analogue in diabetes are related to positive effects on islet cell turnover and transdifferentiation	16
Inhibition of 11β‐Hydroxysteroid dehydrogenase‐1 with AZD4017 in patients with nonalcoholic steatohepatitis or nonalcoholic fatty liver disease: A randomized, double‐blind, placebo‐controll	16
Red cell distribution width in patients with diabetes and myocardial infarction: An analysis from the EXAMINE trial	16
Efficacy and safety of polyethylene glycol loxenatide monotherapy in type 2 diabetes patients: A multicentre, randomized, double‐blind, placebo‐controlled phase 3a clinical trial	16
The impact of the glucagon‐like peptide‐1 receptor agonist liraglutide on natriuretic peptides in heart failure patients with reduced ejection fraction with and without type 2 diabetes	16
Incident heart failure, arrhythmias and cardiovascular outcomes with sodium‐glucose cotransporter 2 (SGLT2) inhibitor use in patients with diabetes: Insights from a global federated electro	16
Cost‐effectiveness analysis of empagliflozin versus sitagliptin as second‐line therapy for treatment in patients with type 2 diabetes in the United States	16
Real‐world performance of the MiniMed 780G advanced hybrid closed loop system in Latin America: Substantial improvement in glycaemic control with each technology iteration of the MiniM	16
Completion of annual diabetes care processes and mortality: A cohort study using the National Diabetes Audit for England and Wales	16
Days absent from work as a result of complications associated with type 2 diabetes: Evidence from 20 years of linked national registry data in Sweden	15
Effect of the glucagon‐like peptide‐1 analogue liraglutide versus placebo treatment on circulating proglucagon‐derived peptides that mediate improvements in body weight, insulin secretion and action:	15
In‐home use of a hybrid closed loop achieves time‐in‐range targets in preschoolers and school children: Results from a randomized, controlled, crossover trial	15
Young adults with nonalcoholic fatty liver disease, defined using the fatty liver index, can be at increased risk of myocardial infarction or stroke	15
A global country‐level analysis of the relationship between obesity and COVID‐19 cases and mortality	15
Change in glucose‐lowering medication regimens in individuals with type 2 diabetes mellitus during the COVID‐19 pandemic in Germany	15
Efficacy of canagliflozin versus metformin in women with polycystic ovary syndrome: A randomized, open‐label, noninferiority trial	15
Non‐steroidal mineralocorticoid antagonists: Prospects for renoprotection in diabetic kidney disease	15
High‐dose sodium‐glucose co‐transporter‐2 inhibitors are superior in type 2 diabetes: A meta‐analysis of randomized clinical trials	15
Distribution patterns of intramyocellular and extramyocellular fat by magnetic resonance imaging in subjects with diabetes, prediabetes and normoglycaemic controls	15
Growth differentiation factor 15 (GDF15) and semaglutide inhibit food intake and body weight through largely distinct, additive mechanisms	15
The effect of dopamine agonists on metabolic variables in adults with type 2 diabetes: A systematic review with meta analysis and trial sequential analysis of randomized clinical trials	15
Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes	15
Epicardial adipose tissue thickness is associated with reduced peak oxygen consumption and systolic reserve in patients with type 2 diabetes and normal heart function	15
Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries	15
Using machine learning to predict severe hypoglycaemia in hospital	15
Glucokinase activation or inactivation: Which will lead to the treatment of type 2 diabetes?	15
The present and future scope of real‐world evidence research in diabetes: What questions can and cannot be answered and what might be possible in the future?	15
Exendin(9‐39)NH₂: Recommendations for clinical use based on a systematic literature review	15
Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials	15
Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials	15
Extended‐release naltrexone/bupropion and liver health: Pooled, post hoc analysis from four randomized controlled trials	15